GHK-RU58841 is used for hair loss, with positive results when combined with finasteride, stemoxydine, redensyl, and alfatradiol. Users report effectiveness after adding finasteride.
A user discusses their habit of analyzing others' hair due to their own hair thinning at 18. Another user mentions starting finasteride in 2010 and still having a full head of hair.
Amplifica has not provided updates on SCUBE3 and AMP-303, raising concerns about their trial outcomes. Users also mention other treatments like Minoxidil, finasteride, RU58841, PP405, and ET-03.
Quercetin might help with hair loss by inhibiting HSP-70, which increases androgen receptors. Concerns include its staining properties and unclear topical absorption.
A young man regrets not starting finasteride treatment for hair loss sooner, noticing significant shedding just two months prior. He advises others experiencing early hair loss to act quickly and start treatment.
The user experienced increased hair shedding after using RU58841, despite initial improvements in scalp condition and appearance. They are considering stopping RU58841 to see if shedding decreases.
The user experienced significant hair regrowth after 9 months of using finasteride, with minimal use of minoxidil. They reported no side effects and emphasized patience and consistency in their treatment routine.
The conversation discusses improvements to a platform and mentions hair loss treatments including Minoxidil, finasteride, RU58841, and melatonin. It also highlights the addition of features like Google login, reply by email, keyword extraction, and a term glossary for better understanding of hair-related terminologies.
A 16-year-old noticed hair thinning on the crown and sides of the head, with minimal temple thinning. After using Minoxidil for 6 months, some areas improved, but the crown worsened, and they seek advice on the irregular hair loss and treatment options.
A Silicon Valley-backed company aims to cure hair loss. Exciting advancements include mRNA therapies, gene editing, hair cloning, AR degraders, anti-androgens, cell-based rejuvenation, and AI-based drug discovery, with hopes for FDA approval of GT20029 within 10 years.
KX-826 users report increased shedding, with some experiencing more shedding at higher concentrations. Users are discussing where to purchase the product.
Procyanidin B2, a compound derived from Annurca apples, as a potential treatment for pattern hair loss. Several clinical studies were mentioned, which found that procyanidin B2 could increase hair growth, density, and keratin content. Other treatments such as Minoxidil, Finasteride, and RU58841 were not discussed.
The user does not respond well to minoxidil and is seeking an alternative to Tretinoin to upregulate sulfurtransferase activity for hair loss treatment. No specific alternative treatments were mentioned.
A 21-year-old is worried about hair loss despite taking 0.5mg finasteride every other day for 7 months. Users suggest continuing treatment, considering a hair transplant, and possibly adding minoxidil.
The user shared progress pictures showing 7-8 months of hair regrowth using Minoxidil, finasteride, Nizoral, dermarolling, and biotin. The hairline remains the same, but overall hair looks better.
Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.
Hair loss involves more than just DHT, with genetic factors like TRPS affecting hair follicles. Treatments such as Amplifica's AMP-601 and AMP-303 target stem cells for potential hair growth solutions.
A 24-year-old woman being diagnosed with androgenic alopecia (AGA) who is scared and confused about her hair loss, and the treatment options of Minoxidil, finasteride, RU58841, spironolactone, and possibly a biopsy.
Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.
Yokohama University and Dr. Fukuda plan human hair multiplication trials in 2023. Users express hope for future hair cloning treatments over current hair transplants.
The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references Epibiotech's hair multiplication and cell therapy as potential solutions.
GHK-Cu is discussed as a potential hair loss treatment, with claims of promoting hair growth and possibly reversing gray hair, though strong clinical evidence is limited. The user also mentions using Minoxidil, red light therapy, and microneedling.
The conversation is about the timeline for Kintor's phase 3 trials for GT20029 and the potential release of the product in three years. It also mentions treatments like Minoxidil, finasteride, and RU58841.
Pyrilutamide/KX-826 is being discussed for its effectiveness in hair regrowth, with some users reporting positive results, especially in early hair loss cases. Users have combined it with treatments like Minoxidil, and some experienced initial shedding before seeing regrowth.
The conversation discusses finding a source for RU58841 in Australia. Users suggest that while RU58841 is effective, it may harm the scalp, and recommend trying koshine's kx as a safer alternative.
The conversation is about a person regrowing their hair in 7 weeks using scalp massages, peppermint oil, microneedling, and keratin shampoo without drugs. They experienced initial shedding but saw improvement after consistent treatment and shampooing every other day.